Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05605067 · ClinicalTrials.gov registry record
Genetic Architecture of Avoidant/Restrictive Food Intake Disorder
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 5,076
- Enrollment target
NCT05605067: Completed study, sponsored by University of North Carolina, Chapel Hill.
NCT05605067 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 5,076 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05605067 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 5,076 participants
- Enrollment target
Study Summary
The goal of this observational study is to rapidly accelerate knowledge about the biology of avoidant and restrictive food intake disorder or ARFID in children ages 7-17 and in adults. The investigators will be evaluating the genetic and environmental origins of ARFID. Participants will be asked to answer questionnaires online and to submit a saliva sample for DNA using a kit that will be mailed to their home.
Primary Outcome
Number of enrolled individuals who meet the case definition
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,076 participants |
| Start Date | 2023-01-05 |
| Est. Completion | 2024-08-01 |
What the finished NCT05605067 record still lists
NCT05605067 is an observational study that tracks outcomes without assigning an intervention. Its 5,076 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05605067 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05605067 about?
NCT05605067 is a clinical study titled "Genetic Architecture of Avoidant/Restrictive Food Intake Disorder". The goal of this observational study is to rapidly accelerate knowledge about the biology of avoidant and restrictive food intake disorder or ARFID in children ages 7-17 and in adults. The investigators will be evaluating the genetic and environmental origins of ARFID. Participants will be asked to ...
What is the current status of trial NCT05605067?
This trial is currently completed. The enrollment target is 5,076 participants. The study started on 2023-01-05. Estimated completion is 2024-08-01.
Who is sponsoring clinical trial NCT05605067?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06292078 · 5,076 participants · NA
Preventing School Exclusion and Opioid Misuse: Effectiveness of the Inclusive Skill-building Learning Approach (ISLA)
- NCT07037459 · 5,056 participants · Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- NCT05018611 · 5,100 participants · NA
Digital Limited Interaction Efficacy Trial of LifeSkills Mobile to Reduce HIV Incidence in YTW
- NCT05701358 · 5,100 participants · NA
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI